NexgenRX (TSX-V: NXG) announced an exclusive supply agreement with CannTrust Inc. (TSX: TRST) this morning. Under the terms of the agreement CannTrust will provide Nexgen Rx patients for an initial 5 year term, that will be renewable if the deal is successful.
NexgenRx’s plans to offer its patients medicinal cannabis from CannTrust’s wide range of products while in conjunction having a portion of that patients percription calculated and applied by their health care plan before purchase. While
checking out patients will be able to pay for their
intended portion of their medicine. This is the first
system that works with individuals health care to
create a seamless process in the check out line.
CannTrust will be offering patients pharmaceutical grade cannabis & cannabis based products in convenient and safe dosages. The company is known for becoming one of the industry leaders in high quality,
standardized medicinal cannabis products.
Ron Loucks, President & CEO of NexgenRx gave this statement in the press release:
“CannTrust® is focused on providing high quality products and service to our patients. Having a real time adjudication process will make it easier and more convenient for NexgenRx plan members to purchase medical cannabis, while maintaining the integrity of health care plans”, said Brad Rogers, President of CannTrust®.”